Loading
A phase 3 trial of sacituzumab tirumotecan and capecitabine in triple-negative breast cancer, run by Fudan University, not yet recruiting.
Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations is a phase 3, randomised interventional study registered as NCT07628504 by Fudan University, with a registry enrolment figure of 420 participants, started 2026-05-18 and due to reach its primary completion in 2030-03-30. Interventions recorded: Sacituzumab Tirumotecan (sac-TMT); Capecitabine. Conditions listed: Adjuvant Drug Therapy. Sites: China. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.